Amplification of HER2 gene in gastric carcinoma detected by dual in-situ hybridization.
- VernacularTitle:应用双重原位杂交检测胃癌HER2基因扩增
- Author:
Lai-fong SIN
1
;
Heong-ting VONG
;
Jian-ming WEN
;
Yuk-ching YIP
Author Information
- Publication Type:Journal Article
- MeSH: Adenocarcinoma; genetics; metabolism; Adult; Aged; Aged, 80 and over; Female; Gene Amplification; Genes, erbB-2; Humans; Immunohistochemistry; In Situ Hybridization; methods; Male; Middle Aged; Receptor, ErbB-2; metabolism; Stomach Neoplasms; genetics; metabolism
- From: Chinese Journal of Pathology 2012;41(3):168-171
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo explore the status of HER2 gene amplification and its product HER2 protein expression in gastric carcinoma, so as to aid in patient selection for anti-HER2 targeted chemotherapy.
METHODSEighty-five cases of gastric carcinoma biopsy tissues were collected. The status of HER2 gene amplification was detected by dual in situ hybridization (dual-ISH). And HER2 protein was detected by immunohistochemistry.
RESULTSHER2 gene amplification was detected in 10/85 (11.8%) cases of gastric carcinoma, and no amplification was detected in 75/85 (88.2%) cases. In the 10 cases with HER2 amplification, HER2 immunoreaction scorings of 3+, 2+ and 0/1+ were present in 7, 2 and 1 cases, respectively. In the 75 cases without HER2 amplification, HER2 immunoreaction scorings of 3+, 2+ and 0/1+ were present in 0, 18 (24.0%) and 57 (76.0%) cases, respectively. Histologically, most gastric carcinoma with amplification of HER2 gene was moderately differentiated tubular adenocarcinoma.
CONCLUSIONSHER2 gene dual-ISH technique is a reliable and objective method for detecting HER2 gene amplification in gastric carcinoma biopsy. Clinically, only few gastric carcinomas show HER2 gene amplification and are suitable candidates for anti-HER2 targeted chemotherapy.
